Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 471

1.

Geographic variation in molecular subtype for gastric adenocarcinoma.

Liao P, Jia F, Teer JK, Knepper TC, Zhou HH, He YJ, McLeod HL.

Gut. 2018 Jun 29. pii: gutjnl-2018-316605. doi: 10.1136/gutjnl-2018-316605. [Epub ahead of print] No abstract available.

PMID:
29960981
2.

Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neill BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook A, Owzar K, Kroetz D.

Clin Cancer Res. 2018 Jun 5. pii: clincanres.1523.2017. doi: 10.1158/1078-0432.CCR-17-1523. [Epub ahead of print]

PMID:
29871907
3.

When will clinical trials finally reflect diversity?

Knepper TC, McLeod HL.

Nature. 2018 May;557(7704):157-159. doi: 10.1038/d41586-018-05049-5. No abstract available.

PMID:
29743700
4.

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators; ACCORD/ACCORDion Investigators.

Diabetes. 2018 Jul;67(7):1428-1440. doi: 10.2337/db17-1164. Epub 2018 Apr 12.

PMID:
29650774
5.

Value of Supportive Care Pharmacogenomics in Oncology Practice.

Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL.

Oncologist. 2018 Apr 5. pii: theoncologist.2017-0599. doi: 10.1634/theoncologist.2017-0599. [Epub ahead of print] Review.

PMID:
29622698
6.

Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology.

He Y, Seminario-Vidal L, McLeod HL.

JAMA Neurol. 2018 Jul 1;75(7):793-795. doi: 10.1001/jamaneurol.2018.0001. No abstract available.

PMID:
29610896
7.

Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.

Wang W, Wang K, Chen Z, Chen L, Guo W, Liao P, Rotroff D, Knepper TC, Liu Z, Zhang W, Mcleod HL, He Y.

Oncotarget. 2018 Jan 6;9(15):12164-12173. doi: 10.18632/oncotarget.24037. eCollection 2018 Feb 23.

8.

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL.

Support Care Cancer. 2018 Aug;26(8):2911-2918. doi: 10.1007/s00520-018-4120-6. Epub 2018 Mar 15.

PMID:
29546524
9.

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH.

Contemp Clin Trials. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10.

PMID:
29535047
10.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30.

PMID:
29460415
11.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

PMID:
29385237
12.

Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.

Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, Walko CM, Teer JK, McLeod HL.

Oncotarget. 2017 Dec 4;8(70):115114-115127. doi: 10.18632/oncotarget.22914. eCollection 2017 Dec 29.

13.

The pharmacogenetics of medications used in general anesthesia.

Xie S, Ma W, Guo Q, Liu J, Li W, McLeod HL, He Y.

Pharmacogenomics. 2018 Feb;19(3):285-298. doi: 10.2217/pgs-2017-0168. Epub 2018 Jan 10.

PMID:
29318929
14.

miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer.

Huang J, He Y, Mcleod HL, Xie Y, Xiao D, Hu H, Chen P, Shen L, Zeng S, Yin X, Ge J, Li L, Tang L, Ma J, Chen Z.

BMC Cancer. 2017 Dec 22;17(1):886. doi: 10.1186/s12885-017-3875-3.

15.

Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance.

Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL.

Pharmacogenomics J. 2018 May 22;18(3):467-473. doi: 10.1038/tpj.2017.41. Epub 2017 Dec 5.

PMID:
29205205
16.

The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.

Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):413-417. doi: 10.1007/s00280-017-3487-2. Epub 2017 Nov 20.

PMID:
29159476
17.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

PMID:
29152729
18.

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, Lertora JJL, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH.

Clin Pharmacol Ther. 2018 Mar;103(3):390-394. doi: 10.1002/cpt.890. Epub 2017 Nov 6.

PMID:
29105735
19.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

PMID:
28877533
20.

Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat.

Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S.

J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. doi: 10.1089/jayao.2017.0051. Epub 2017 Aug 4. No abstract available.

21.

Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way.

Wang W, Liu J, He Y, McLeod HL.

Pharmacogenomics. 2017 Aug;18(13):1299-1304. doi: 10.2217/pgs-2017-0053. Epub 2017 Jul 26. Review.

PMID:
28745931
22.

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Clin Pharmacol Ther. 2018 Apr;103(4):712-721. doi: 10.1002/cpt.798. Epub 2017 Nov 3.

PMID:
28736931
23.

EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients.

Shen H, Zhong M, Wang W, Liao P, Yin X, Rotroff D, Knepper TC, Mcleod HL, Zhou C, Xie S, Li W, Xu B, He Y.

Clin Chim Acta. 2017 Aug;471:216-221. doi: 10.1016/j.cca.2017.06.006. Epub 2017 Jun 7.

PMID:
28601671
24.

Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.

Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL.

J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23. No abstract available.

PMID:
28549953
25.

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial.

Marvel SW, Rotroff DM, Wagner MJ, Buse JB, Havener TM, McLeod HL, Motsinger-Reif AA; The ACCORD/ACCORDion Investigators.

PeerJ. 2017 May 2;5:e3187. doi: 10.7717/peerj.3187. eCollection 2017.

26.

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS.

JAMA Dermatol. 2017 Jun 1;153(6):607-609. doi: 10.1001/jamadermatol.2017.0187. No abstract available.

PMID:
28384659
27.

Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research.

Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ, McLeod HL, Roden D, Rodriguez LL, Williams MS, Cooper GM, Cox NJ, Herman GE, Kingsmore S, Lo C, Lutz C, MacRae CA, Nussbaum RL, Ordovas JM, Ramos EM, Robinson PN, Rubinstein WS, Seidman C, Stranger BE, Wang H, Westerfield M, Bult C.

Cell. 2017 Mar 23;169(1):6-12. doi: 10.1016/j.cell.2017.03.005.

28.

Strategies for integrating personalized medicine into healthcare practice.

Pritchard DE, Moeckel F, Villa MS, Housman LT, McCarty CA, McLeod HL.

Per Med. 2017 Mar;14(2):141-152. doi: 10.2217/pme-2016-0064. Epub 2017 Jan 19.

29.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
30.

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.

Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 8.

31.

Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.

Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL.

Oncologist. 2017 Feb;22(2):208-212. doi: 10.1634/theoncologist.2016-0233. Epub 2017 Feb 6.

32.

American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data.

Jim HS, McLeod HL.

J Clin Oncol. 2017 Apr 1;35(10):1133-1134. doi: 10.1200/JCO.2016.69.2079. Epub 2017 Feb 6. No abstract available.

PMID:
28165908
33.

Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.

Jia F, Teer JK, Knepper TC, Lee JK, Zhou HH, He YJ, McLeod HL.

Mol Diagn Ther. 2017 Apr;21(2):179-185. doi: 10.1007/s40291-016-0250-z.

34.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [Epub ahead of print] Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349.

35.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
36.

Somatic cancer variant curation and harmonization through consensus minimum variant level data.

Ritter DI, Roychowdhury S, Roy A, Rao S, Landrum MJ, Sonkin D, Shekar M, Davis CF, Hart RK, Micheel C, Weaver M, Van Allen EM, Parsons DW, McLeod HL, Watson MS, Plon SE, Kulkarni S, Madhavan S; ClinGen Somatic Cancer Working Group.

Genome Med. 2016 Nov 4;8(1):117.

37.

The pharmacogenomics of drug resistance to protein kinase inhibitors.

Gillis NK, McLeod HL.

Drug Resist Updat. 2016 Sep;28:28-42. doi: 10.1016/j.drup.2016.06.008. Epub 2016 Jul 5. Review.

38.

Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.

Zhou C, Chen X, Zeng W, Peng C, Huang G, Li X, Ouyang Z, Luo Y, Xu X, Xu B, Wang W, He R, Zhang X, Zhang L, Liu J, Knepper TC, He Y, McLeod HL.

Oncotarget. 2016 Oct 18;7(42):68314-68327. doi: 10.18632/oncotarget.11599.

39.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

40.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

41.

Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers.

Jia FF, Tan ZR, McLeod HL, Chen Y, Ou-Yang DS, Zhou HH.

Xenobiotica. 2016 Oct;46(10):896-900. doi: 10.3109/00498254.2015.1132792. Epub 2016 Feb 29.

PMID:
26928207
42.

A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure.

Jackson JN, Long KM, He Y, Motsinger-Reif AA, McLeod HL, Jack J.

Pharmacogenet Genomics. 2016 Jan 1. [Epub ahead of print]

43.

Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Miranda-Massari JR, Rodríguez-Gómez JR, González MJ, Cidre C, Duconge J, Marín H, Grace K, McLeod HL.

Int J Diabetes Res. 2016;5(5):92-101.

44.

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.

Bell GC, Donovan KA, McLeod HL.

Cancer Control. 2015 Oct;22(4):426-32. Review.

PMID:
26678969
45.

The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference.

He RH, He YJ, Tang YJ, Zhou HH, McLeod HL, Liu J.

Pharmacogenomics. 2016;17(1):74-9. doi: 10.2217/pgs.15.152. Epub 2015 Dec 14. Review.

PMID:
26652861
46.

Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology.

Deverka P, Messner DA, McCormack R, Lyman GH, Piper M, Bradley L, Parkinson D, Nelson D, McLeod HL, Smith ML, Jacques L, Dutta T, Tunis SR.

Genet Med. 2016 Aug;18(8):780-7. doi: 10.1038/gim.2015.162. Epub 2015 Dec 3. Erratum in: Genet Med. 2016 Jun;18(6):650.

PMID:
26633547
47.

Integrated patient and tumor genetic testing for individualized cancer therapy.

Hertz DL, McLeod HL.

Clin Pharmacol Ther. 2016 Feb;99(2):143-6. doi: 10.1002/cpt.294. Epub 2015 Nov 25.

PMID:
26537014
48.

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM.

Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20. Review.

49.

Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.

Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, Inunchot W, Somboonyosdes C, Wichukchinda N, Sawanpanyalert P, He Y, McLeod HL, Chantratita W.

J Hum Genet. 2016 Feb;61(2):119-27. doi: 10.1038/jhg.2015.115. Epub 2015 Oct 1.

PMID:
26423926
50.

PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.

Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170. Review. No abstract available.

Supplemental Content

Loading ...
Support Center